Acceleron Pharma Inc. (NASDAQ:XLRN) SVP Christopher Rovaldi sold 14,000 shares of Acceleron Pharma stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the transaction, the senior vice president now owns 28,232 shares in the company, valued at approximately $1,084,391.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Acceleron Pharma Inc. (NASDAQ XLRN) opened at 39.91 on Friday. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $41.69. The stock’s market cap is $1.54 billion. The stock’s 50 day moving average price is $35.71 and its 200-day moving average price is $30.87.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same quarter in the previous year, the company posted ($0.59) EPS. The company’s revenue was down 3.1% compared to the same quarter last year. Equities analysts anticipate that Acceleron Pharma Inc. will post ($2.72) earnings per share for the current fiscal year.
WARNING: “Acceleron Pharma Inc. (XLRN) SVP Sells $537,740.00 in Stock” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/acceleron-pharma-inc-xlrn-svp-sells-537740-00-in-stock.html.
Several institutional investors and hedge funds have recently added to or reduced their stakes in XLRN. BNP Paribas Arbitrage SA increased its holdings in shares of Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 3,288 shares during the last quarter. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Acceleron Pharma in the 2nd quarter valued at about $213,000. Bank of Montreal Can purchased a new position in shares of Acceleron Pharma in the 1st quarter valued at about $237,000. Parametric Portfolio Associates LLC purchased a new position in shares of Acceleron Pharma in the 1st quarter valued at about $241,000. Finally, Tudor Investment Corp ET AL increased its holdings in shares of Acceleron Pharma by 8.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 716 shares during the last quarter. Institutional investors and hedge funds own 88.07% of the company’s stock.
XLRN has been the topic of several analyst reports. Cann reiterated a “buy” rating and issued a $40.00 target price on shares of Acceleron Pharma in a research note on Thursday, June 1st. Piper Jaffray Companies lifted their target price on Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. BidaskClub upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. CIBC lowered Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. Finally, Morgan Stanley cut their target price on Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $42.33.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.